| abstract |
Development of an influenza vaccine nasal powder that can be stored at room temperature and can deliver a fixed amount of antigen directly to the target site (nasal shell, nasopharynx) by nasal inoculation. An influenza vaccine antigen (component-1), a pharmaceutically acceptable saccharide or polyol (component-2), and a pharmaceutically acceptable additive that is not water soluble and hygroscopic (component-3) Nasal powder containing. |